(Q38095809)

28 August 2017

The evolving role of antifungal susceptibility testing (English)

1 reference

28 August 2017

Gregory A Eschenauer

1

1 reference

PubMed ID

23553342

28 August 2017

Peggy L Carver

series ordinal

2

1 reference

PubMed ID

23553342

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

33

1 reference

28 August 2017

5

1 reference

28 August 2017

465-475

1 reference

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing

28 August 2017

1 reference

To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias.

21 January 2018

1 reference

In vitro susceptibility testing in fungi: a global perspective on a variety of methods

21 January 2018

1 reference

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

Has antifungal susceptibility testing come of age?

21 January 2018

1 reference

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods

21 January 2018

1 reference

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria

21 January 2018

1 reference

Setting and revising antibacterial susceptibility breakpoints

21 January 2018

1 reference

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species

21 January 2018

1 reference

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

21 January 2018

1 reference

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution

21 January 2018

1 reference

Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia

21 January 2018

1 reference

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

21 January 2018

1 reference

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

21 January 2018

1 reference

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

21 January 2018

1 reference

Association of fluconazole pharmacodynamics with mortality in patients with candidemia

21 January 2018

1 reference

Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection

21 January 2018

1 reference

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

21 January 2018

1 reference

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata

21 January 2018

1 reference

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

21 January 2018

1 reference

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

21 January 2018

1 reference

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

21 January 2018

1 reference

Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

21 January 2018

1 reference

Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata

21 January 2018

1 reference

Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.

21 January 2018

1 reference

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin

21 January 2018

1 reference

Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

21 January 2018

1 reference

The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata

21 January 2018

1 reference

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

21 January 2018

1 reference

Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility

21 January 2018

1 reference

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

21 January 2018

1 reference

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

21 January 2018

1 reference

Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.

21 January 2018

1 reference

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome

21 January 2018

1 reference

Azole-resistance in Aspergillus: proposed nomenclature and breakpoints

21 January 2018

1 reference

Infections caused by Scedosporium spp.

21 January 2018

1 reference

Fusarium infections in immunocompromised patients

21 January 2018

1 reference

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

21 January 2018

1 reference

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles

21 January 2018

1 reference

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

21 January 2018

1 reference

Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.

21 January 2018

1 reference

Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

21 January 2018

1 reference

In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1233

1 reference

28 August 2017

1 reference

PubMed ID

23553342